Prostaglandin E2 induces the expression of functional inhibitory CD94/NKG2A receptors in human CD8+ T lymphocytes by a cAMP-dependent protein kinase A type I pathway
- 1 September 2005
- journal article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 70 (5), 714-724
- https://doi.org/10.1016/j.bcp.2005.05.015
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Cyclooxygenase‐2 and 5‐lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapyThe FASEB Journal, 2003
- ErratumImmunity, 2002
- Specificity in the cAMP/PKA signaling pathway. differential expression, regulation, and subcellular localization of subunits of PKAFrontiers in Bioscience-Landmark, 2000
- Opposite regulation of prostaglandin E2 synthesis by transforming growth factor-β1 and interleukin 10 in activated microglial culturesJournal of Neuroimmunology, 1998
- NKG2A Complexed with CD94 Defines a Novel Inhibitory Natural Killer Cell ReceptorThe Journal of Experimental Medicine, 1997
- The CD94 and NKG2‐A C‐type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I moleculesEuropean Journal of Immunology, 1997
- Molecular characterization of human CD94: A type II membrane glycoprotein related to the C‐type lectin superfamilyEuropean Journal of Immunology, 1995
- Novel (Rp)-cAMPS Analogs as Tools for Inhibition of cAMP-kinase in Cell CulturePublished by Elsevier BV ,1995
- Targeting of T lymphocytes against egf‐receptor+ tumor cells by bispecific monoclonal antibodies: Requirement of CD3 molecule cross‐linking for t‐cell activationInternational Journal of Cancer, 1993
- The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune responseImmunology Today, 1988